Table 3.
Means (± Standard deviations) of primary and secondary clinical measures of depression severity by treatment assignment.
| Treatment | N | Depression Measure | Mean Score (± Standard Deviation) | Number of Participants | |||
|---|---|---|---|---|---|---|---|
| Baseline | Week 4 | Change | Respondersa | Nonresponders | |||
| Sertraline | 55 | ||||||
| QIDS-C | 16.4 (± 3.3) | 8.5 (± 4.3) | -7.9 (± 4.9) *** | 27 | 28 | ||
| HDRS-17 | 24.9 (± 2.8) | 11.5 (± 5.8) | -13.4 (± 5.7) *** | 33 | 22 | ||
| QIDS-SR | 15.8 (± 3.7) | 8.1 (± 4.7) | -7.7 (± 5.5) *** | 29 | 26 | ||
| Placebo | 50 | ||||||
| QIDS-C | 17.4 (± 2.8) | 9.2 (± 4.6) | -8.2 (± 4.7) *** | 24 | 26 | ||
| HDRS-17 | 24.6 (± 2.5) | 13.9 (± 6.4) | -10.7 (± 6.6) *** | 20 | 30 | ||
| QIDS-SR | 16.6 (± 3.6) | 8.8 (± 4.6) | -7.9 (± 4.3) *** | 25 | 25 | ||
***
p. < .001
a
Responder = 50% or greater reduction of depression severity from baseline to Week 4